Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
rAAV2tYF-CB-hRS1 / AGTC
NCT02416622: Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS) Efficacy data in patients with X-linked Retinoschisis Dec 2018 - Dec 2018: Efficacy data in patients with X-linked Retinoschisis Data on the dose escalation phase for X-linked retinoschisis Jun 2017 - Jun 2017: Data on the dose escalation phase for X-linked retinoschisis Data on the dose escalation phase for X-linked retinoschisis Jun 2017 - Jun 2017: Data on the dose escalation phase for X-linked retinoschisis More	Completed	1/2	27	US	rAAV2tYF-CB-hRS1	Applied Genetic Technologies Corp	X-linked Retinoschisis	04/19	05/23
NCT02317887: Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis	Active, not recruiting	1/2	12	US	RS1 AAV Vector	VegaVect, Inc., National Eye Institute (NEI)	Retinoschisis, X-Linked	07/25	07/25
NCT06066008: Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients	Recruiting	1	9	RoW	ZM-01-L, rAAV-hRS1, ZM-01-H	Zhongmou Therapeutics	X-linked Retinoschisis	10/23	10/27